Prucalopride Improves Bowel Function and Colonic Transit Time in Patients With Chronic Constipation: An Integrated Analysis

OBJECTIVES: Constipation is often characterized by slow colonic transit, but the relationship between colonic transit time (CTT) and symptoms is unclear. The aims of this study were to investigate the effect of prucalopride, a 5-hydroxytryptamine receptor-4 agonist, on CTT and assess the relationship between CTT and symptoms. METHODS: This was an integrated analysis of three randomized, placebo-controlled, phase 2 dose-fi nding trials of prucalopride in patients with chronic constipation (ClinicalTrials.gov identifi ers: NCT00617513; NCT00631813; and NCT00596596). Measurements of CTT were analyzed using radio-opaque markers at the start and end (4 or 12 weeks) of treatment. At these visits, patients assessed the presence and severity of their symptoms. RESULTS: In total, 280 patients had CTT measurements before and at the end of treatment and were included in the analysis. Their mean age was 43 years, 93 % were women, and mean duration of constipation was 19 years. After a once daily treatment with prucalopride 2 mg ( n = 98) and 4 mg ( n = 70), CTT was reduced by 12.0 h (95 % confi dence interval (CI): ‐ 18.9, ‐ 5.1) and 13.9 h (95 % CI: ‐ 20.5, ‐ 7.4), respectively; CTT increased by 0.5 h (95 % CI: ‐ 4.5, 5.5) with placebo ( n = 112). At the end of the trial, symptoms including bloating / fl atulence / distension and straining were rated as severe or very severe by a higher proportion of patients with slow or very slow CTT ( > 48 h) than by those with normal CTT. CONCLUSIONS: There was a clear relationship between increased CTT and increased symptom severity in patients with chronic constipation. Treatment with prucalopride accelerated CTT in these individuals.